



Blastocystis and irritable bowel syndrome: Frequency and subtypes from Iranian patients



Shahram Khademvatan^{a,b,*}, Rahim Masjedizadeh^{a,**}, Fakher Rahim^a, Hamidreza Mahbodfar^a, Roya Salehi^a, Ehsan Yousefi-Razin^c, Masoud Foroutan^d

^a Research Institute for Infectious Diseases of Digestive System, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

^b Department of Medical Parasitology and Mycology & Cellular and Molecular Research Center, Urmia University of Medical Sciences, Urmia, Iran

^c Department of Genetics, Shahid Beheshti University of Medical Science, Tehran, Iran

^d Department of Parasitology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran

ARTICLE INFO

Article history:

Received 23 September 2016

Received in revised form 4 January 2017

Accepted 9 January 2017

Available online 10 January 2017

Keywords:

Irritable bowel syndrome

Blastocystis

Subtype

Iran

ABSTRACT

There are inconsistent findings about the role of *Blastocystis* infection in irritable bowel syndrome (IBS). The present study was aimed to determine the frequency of *Blastocystis* and their subtypes (ST) in patients with IBS. A total of 122 patients with IBS and 122 healthy individuals referred to the medical laboratory centers in Ahvaz (southwest of Iran) participated in the study. The frequency of *Blastocystis* was determined. *Blastocystis* genomic DNA was extracted from positive feces, and PCR was performed using seven primer pairs targeting the SSU rDNA gene. *Blastocystis* was detected in 19.67% of patients with IBS and 17.2% of individuals without IBS. The difference between two groups was not statistically significant ($P = 0.3$). Among the five subtypes of *Blastocystis*, ST3 was more common in patients with IBS and control group. However, there were no significant differences between two groups in terms of subtypes of *Blastocystis* ($P = 0.6$). It seems, the role of *Blastocystis* in the etiology of IBS should be further investigated. Furthermore, a model of study should be designed to investigate the role of host factors in severity of parasitic disease.

© 2017 Published by Elsevier Ireland Ltd.

1. Introduction

Irritable bowel syndrome (IBS) is a chronic functional disorder of the gastrointestinal tract. It is a common healthcare problem with worldwide distribution that reduces the quality of life [1]. Young adults and people over the age of 50 years are more prone to IBS, and women are 2–3 times more frequently exposed [2]. The disease is characterized by abdominal pain, flatulence, irregular bowel movements and, diarrhea or constipation in the absence of organic etiology [1]. According to the widely used Rome II criteria, IBS sufferers can be clustered into three symptom groups based on the stool appearance, stool frequency, and defecatory symptoms: diarrhea (IBS-D), constipation (IBS-C), and mixed type (IBS-M) with alternating occurrence of both diarrhea and constipation [1,2]. More recently, the Rome III criteria, which focused on the symptom frequency over persistence, have been issued [2].

IBS is one of the most common complaints that disturbs the socio-economical life of patients [3]. The disease has a high prevalence in western countries ranging between 12–15% [4]. In Asian countries, some studies have shown the prevalence of IBS between 3.5–25% [5]. Several epidemiological studies have recorded the prevalence of IBS in Iran to vary between 4% to 12.6% [6]. The causes and pathophysiology of IBS are unknown. Several factors, including visceral hypersensitivity, irregular gut motility, and autonomous nervous system dysfunction are reported as probable causes of the signs and symptoms of IBS. Other studies have shown that genetic factors, chronic stress, and chronic immune activation can predispose people to developing IBS [7,8]. There is reliable evidence showing that IBS may be the result of an acute infectious gastroenteritis, post infection (PI_ IBS); the infectious agents involved in the development of IBS include pathogenic bacteria, viruses, and parasites [9]. One of the parasites that may be involved in the development of IBS is *Blastocystis*; an enteric cosmopolitan protist and one of the most common parasites found in stool samples [9]. The prevalence of *Blastocystis* has been reported in the variable range from 1.5% to 10% and 30 to 50% in the developed and developing countries, respectively [10].

There has been debate concerning the pathogenicity of *Blastocystis* in several studies [35]. Some of these studies specified an association between the parasite and IBS [11–14], while others did not report

* Correspondence to: S. Khademvatan, Research Institute for Infectious Diseases of Digestive System, Ahvaz Jundishapur University of Medical Sciences, and Cellular and Molecular Research Center, Urmia University of Medical Sciences, Urmia, PO Box: 613715794, Iran.

** Corresponding author.

E-mail addresses: Khademvatan@yahoo.com (S. Khademvatan), Rahim.masjedi@gmail.com (R. Masjedizadeh).

association that have been attributed with IBS [10,15]. Molecular and phylogenetic studies suggested that humans can involve with multiple subtypes of *Blastocystis*, as well as a number of factors such as intensity of infection, host immunity and parasite subtypes (STs) are considered for its pathogenicity [16,17]. The presence of sufficient information on the subtypes of *Blastocystis* found in IBS patients would be of interest in understanding the importance and role of *Blastocystis* infection in chronic illness. Thus, this study aimed to determine the frequency and identify *Blastocystis* subtypes in patients with IBS, in Ahvaz, southwest-iran.

2. Materials and methods

2.1. Study area

Ahvaz city, capital of Khuzestan province which is located in the southwest of Iran (31°50'N and 49°11'E), is ranked as the 7th largest city throughout the country and based on the latest census, its population was calculated 1,395,184 in 352,128 families. Weather temperature is highly variable throughout the year so that in summer temperature exceeds 50 °C whereas in winter it falls to 5 °C. Also, annual average rainfall is approximately 230 mm [33].

2.2. Study design and population

This descriptive study was conducted over a period of 24 months from 2012 to 2014. The sample of the study consisted of 244 subjects (122 patients diagnosed with IBS and 122 individuals without IBS, with the age range of participants was 20–50 years) who were referred to the medical laboratory centers of Ahvaz, southwest of Iran by a gastroenterologist. Ethical approval was obtained from the Committee of Research, Publications and Ethics of the Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences. Before collecting stool samples, a written informed consent was obtained from participants.

2.3. Inclusion criteria

Patients were classified according to Rome III criteria as IBS category. According to these diagnostic criteria, IBS was defined by recurrent abdominal pain or discomfort at least 3-day per month in the last 3-month, associated with two or more of the following: improvement with defecation, onset associated with a change in frequency of stool, and onset associated with a change in form (appearance) of stool. Information about their medical history was obtained.

2.4. Exclusion criteria

Patients with pregnancy, the presence of thyroid disorders, chronic diseases, e.g., chronic liver or kidney diseases; intestinal surgery such as appendectomy and choledochotomy; being under antibiotic treatment during last month, being under chemotherapy.

2.5. Stool collection and examination

Fecal specimens were obtained from both IBS and control groups. The consistency of all stool samples, including formed, soft, loose, and watery was noted. All samples were examined through wet and lugol smears. Stool examination was performed and *Blastocystis*-positive stools were stained by Trichrome method.

2.6. DNA extraction

Genomic DNA of each isolate was extracted using a DNA extraction kit according to the manufacturer's protocol (QIAamp, QIAGEN Inc., Germany). Stool specimens that were co-infected with other parasites

were excluded. Eventually, the extracted DNA was stored at –20 °C until PCR amplification.

2.7. Subtyping

PCR was performed using specific *sequence-tagged site* (STS) primers to identify subtypes of *Blastocystis*, including SB83 (351 bp) for ST1, SB340 (704 bp) for ST2, SB227 (526 bp) for ST3, SB337 (487 bp) for ST4, SB336 (317 bp) for ST5, SB332 (338 bp) for ST6, and SB155 (650 bp) for ST7 [18]. PCR reaction mixtures (25 µl of total volume) consisted of PCR buffer 1 × [10 mM Tris-HCl, pH 8.8, and 50 mM KCl], 1.5 mM MgCl₂, 2.5 U/µl of *Taq* polymerase (Fermentas), 1.25 µM of each dNTPs (Fermentas), 0.5 pmol of each primer, and 5 µl of the DNA sample. The PCR conditions consisted of one cycle denaturing at 94 °C for 5 min, 40 cycles, including annealing at 57 °C for 30 s, extending at 72 °C for 60 s, denaturing at 94 °C for 30 s, and additional cycle with 5-min chain elongation at 72 °C (MyCycler, Bio-Rad, Hercules, CA, USA). The amplification products were electrophoresed on 2% agarose gels and Tris-borate-EDTA buffer. Gels were stained with ethidium bromide and photographed using an ultraviolet gel documentation system (Uvidoc, Gel Documentation System, Cambridge, UK) [33,34]. The PCR amplification for each primer pair was done thrice for each isolate.

2.8. Sequence analysis

PCR amplification of sequences from 23 randomly selected *Blastocystis* isolates was performed by MWG (Biotech AG, Germany), and were analyzed and graphics were generated using Chromas 2.23 software (Technelysium Pty Ltd. Australia). Sequences were individually compared with *Blastocystis* SSU-rRNA gene sequences available in GenBank using the basic local alignment search tool (BLAST) algorithm. Each sequence was then aligned with a panel of reference sequences from GenBank using the ClustalW program to determine sequence similarity.

2.9. Statistical analysis

Data were analyzed using Chi-square test and Fisher's exact test. A *P* value < 0.05 was considered as significant. Statistical analysis was carried out using SPSS v18.

3. Results

Among patients with IBS, 55% (*n* = 67) were male and 45% (*n* = 55) were female. The mean age of the patients was 38 years. The control group consisted of 64 (52.45%) males and 58 (47.55%) females; the mean age of this group was 31 years. There was no significant difference between the two groups in age and gender (*P* > 0.05). Individuals' chief complaints were abdominal pain, diarrhea, and constipation. Frequency of participants with different symptoms of IBS are listed in Table 1. *Blastocystis* was detected in 19.67% (*n* = 24) of patients with IBS and 17.2% (*n* = 21) of individuals without IBS. There were no significant differences in *Blastocystis* between two groups (*P* = 0.3). Prevalence of *Blastocystis* in participants with different stool consistency was reported in Table 2.

Table 1
Frequency of symptoms in IBS and control group.

Symptoms	IBS group	Control group	<i>P</i> -value
Abdominal pain	73 (59.8%)	13 (10.6%)	<i>P</i> < 0.05
Diarrhea	27 (22.1%)	16 (13.1%)	<i>P</i> < 0.05
Constipation	30 (24.5%)	17 (13.9%)	<i>P</i> < 0.05
Alternating diarrhea/constipation	36 (29.5%)	9 (7.3%)	<i>P</i> < 0.05

Table 2
Frequency of *Blastocystis* in participants with different stool consistency.

	Stool Consistency Frequency (%)	Formed No. (%)	Soft No. (%)	Loosed No. (%)	Watery No. (%)	Total No. (%)	P-value
Patients with IBS	<i>Blastocystis</i> positive	6/42 (14.28%)	9/51 (17.64%)	4/12 (33.33%)	5/17 (29.41%)	24/122 (19.67%)	0.34
Control group	<i>Blastocystis</i> positive	4/68 (5.88%)	6/35 (17.14%)	6/6 (100%)	5/13 (38.46%)	21/122 (17.21%)	<0.001

In both groups, *Blastocystis* was more prevalent in participants with loosed and watery stool. There were significant differences in prevalence of *Blastocystis* among individuals of the control group with different stool consistency ($P < 0.001$) and, *Blastocystis* was more prevalent in participants with loosed stool. However, there was no significant difference between patients with IBS in this regard ($P = 0.34$) (Table 2). Subtypes of *Blastocystis* sp. were identified by PCR. The most frequent genotype was ST3 (50%) in patients with IBS, and (42.85%) in the control group. There was no significant difference between two groups in subtypes of *Blastocystis* sp. ($P = 0.6$) (Table 3).

Multiple sequence alignment of randomly selected samples confirmed the PCR results; DNA sequences from isolates were aligned with the SSU rDNA gene of their closest match reference strains from GenBank. Comparative molecular analysis of *Blastocystis* sequences with other GenBank sequence STs showed high similarity to homologous sequences from previously reported *Blastocystis* isolates stored in GenBank (<http://www.ncbi.nlm.nih.gov/nucleotide/>).

4. Discussion

IBS is the most prevalent functional gastrointestinal disorder with a worldwide distribution [5]. Studies from Europe and the Middle East have found that approximately 30–40% of IBS patients are *Blastocystis* carriers [2,5]. As *Blastocystis* sp. can be found in both symptomatic and asymptomatic patients, there are conflicting views about its pathogenicity. However, an increasingly number of studies cited the pathogenic potential of *Blastocystis* sp. [14,16,19]. The prevalence of *Blastocystis* in the IBS and control groups was not significantly different ($P = 0.3$). Our finding was in agreement with those reports of no relationship between presence of *Blastocystis* in feces and diagnosis of IBS [10,15]. In contrast, in the studies conducted by Boorum et al., [20] and, Yakoob et al., [13], association between *Blastocystis* and IBS was suggested, and *Blastocystis* was more frequently demonstrated in the fecal samples of IBS patients than in control group. Nevertheless, some authors have suggested that the abnormal intestinal tract provides conditions suitable for the proliferation of *Blastocystis*. It is possible that *Blastocystis* infection is a sign of intestinal disorder rather than a cause of IBS. Whenever *Blastocystis* is detected in stool samples of patients with IBS, it does not necessarily mean that the symptoms are due to this organism, and other infective and non-infectious causes should be investigated [10,21].

It has been considered that molecular variation and different subtypes may be correlated with the pathogenic potential of *Blastocystis* [13,19]. In this study, ST3 in both IBS and control groups were shown to have higher prevalence than the others. ST3 is the most prevalent ST in the human population in various symptomatic and asymptomatic people followed by ST1 [11,22,23]. In a study by Dogruman-Al et al., *Blastocystis* subtypes identified in patients presenting with IBS, IBD,

chronic diarrhea and asymptomatic patients in Turkey and subtypes 2 and 3 were associated with chronic infection in both symptomatic and asymptomatic individuals [11]. Previously, a possible link between subtype 2 and asymptomatic infections of *Blastocystis* was reported [12]; whereas in our results subtype 2 was not observed in either symptomatic or asymptomatic groups.

Our phylogenetic analysis in patients presenting with IBS suffering from chronic diarrhea showed subtype 4 as a zoonotic subtype that is commonly found in rats and wild birds. Interestingly, in studies done by Dominguez-Marques et al., and Stensvold et al., also found a strong preponderance (94.1% and 76.0%, respectively) of ST4 among individuals suffering mainly from acute diarrhea [24,25]. Previous works in contrast with our findings mentioned that zoonotic subtypes (subtypes 4, 6, 7), have not been commonly found in patients with chronic infections [20]. These complicated results showed no significance in the difference in the distribution of *Blastocystis* STs between IBS and control groups, and symptoms were probably associated with host genetics, immunity, or intensity of infection. A similar event has been reported in amoebiasis, where the identical strain caused asymptomatic or severe symptomatic infection in different peoples [26]. Similar to *Entamoeba histolytica* infection in which effective cytokine may lead to the expression of symptoms, production of high levels of TNF- α cytokine and low levels of immunosuppressive IL-10 are over-represented in the IBS population [26,27]. Also, a 29-kDa parasite protein and a parasite associated protease has been noted as potential markers of pathogenicity [28]. Apoptosis of intestinal cells, epithelial barrier function disturbance, and modulation of host immune response are other pathological factors exploited by *Blastocystis* [29].

It has been suggested that low-grade inflammation, due to ongoing immune activation caused by carriage or infection with *Blastocystis*, providing persistent antigenic exposure, could play a role in IBS [21]. In this study, the predominant symptom in the IBS group was abdominal pain. The main reason for gastrointestinal symptoms in IBS patient is thought to be serine protease production [30]. Secretion of proteases at high levels is protozoa-specific and is not found in bacterial or viral infection. This enzyme damaged intestinal permeability and caused diarrhea in IBS patients [31]. Also, proteases are produced by *Blastocystis* to degrade secretory IgA as a defense mechanism. The release of high levels of IgA is a common factor in symptomatic, but not asymptomatic, cases of *Blastocystis* [32].

In conclusion, in this study, *Blastocystis* ST3 and ST1 were the most frequently detected, subtypes, and their prevalence were not significantly different in IBS and control groups. The study of *Blastocystis* that specifically identifies the subtype of *Blastocystis* in patients' pathogenic behavior in those subtypes may help us better understand the role of this protist infection in complicated chronic intestinal disease, such as IBS. We suggest that further studies are needed to control and eliminate the effect of other pathogens and host factors to understand the correlation between *Blastocystis* and IBS.

Table 3
Blastocystis subtypes in patients with IBS and control group.

Subtype	I No. (%)	II No. (%)	III No. (%)	IV No. (%)	V No. (%)	Mix No. (%)	P-value
Patients with IBS	9/24 (37.5%)	0/24 (0%)	12/24 (50%)	2/24 (8.33%)	1/24 (4.16%)	0 (0%)	0.6
Subjects of control group	8/21 (38.09%)	0/21 (0%)	9/21 (42.85%)	1/21 (4.76%)	3/21 (14.28%)	0 (0%)	

Funding

This study was supported by the research project of the Research Institute for Infectious Diseases of Digestive System, Ahvaz Jundishapur University of Medical Sciences no: RDC9108.

Conflict of interest

The authors declare no conflict of interests.

Ethical statement

Ethical approval was obtained from the Committee of Research, Publications and Ethics of the Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences. Before collecting stool samples, a written informed consent was obtained from all subjects.

Acknowledgments

The authors would like to thank Mr. Shakouri and Mr. Ghasemi for their help in collecting the samples.

References

- [1] G.F. Longstreth, W.G. Thompson, W.D. Chey, L.A. Houghton, F. Mearin, R.C. Spiller, Functional bowel disorders, *Gastroenterology* 130 (2006) 1480–1491.
- [2] D.W. Park, O.Y. Lee, S.G. Shim, D.W. Jun, K.N. Lee, H.Y. Kim, et al., The differences in prevalence and sociodemographic characteristics of irritable bowel syndrome according to Rome II and Rome III, *Neurogastroenterol. Motil.* 16 (2010) 186–193.
- [3] P. Jafari, Z. Asadollahi, M. Moini, M.M. Seyed, Health related quality of life in Iranian patients with irritable bowel syndrome: reliability and validity of the persian version of the IBS-QOL, *Iran Red Crescent Med. J.* 15 (2013) 723–728.
- [4] L. Agreus, K. Svardsudd, O. Nyren, G. Tibblin, Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time, *Gastroenterology* 109 (1995) 671–680.
- [5] F. Cremonini, N.J. Talley, Irritable bowel syndrome: epidemiology, natural history, health care seeking and emerging risk factors, *Gastroenterol. Clin. N. Am.* 34 (2005) 189–204.
- [6] D. Roshandel, M. Rezaileshkajani, S. Shafaei, M.R. Zali, A cost analysis of functional bowel disorders in Iran, *Int. J. Color. Dis.* 22 (2007) 791–799.
- [7] A. Salonen, W.M. de Vos, A. Palva, Gastrointestinal microbiota in irritable bowel syndrome: present state and perspectives, *Microbiology* 156 (2010) 3205–3215.
- [8] S. Khan, L. Chang, Diagnosis and management of IBS, *Nat. Rev. Gastroenterol. Hepatol.* 7 (2010) 565–581.
- [9] G. Barbara, C. Cremon, F. Pallotti, R. De Giorgio, V. Stanghellini, R. Corinaldesi, Postinfectious irritable bowel syndrome, *J. Pediatr. Gastroenterol. Nutr.* 48 (Suppl. 2) (2009) S95–S97.
- [10] I. Wawrzyniak, P. Poirier, E. Viscogliosi, M. Dionigia, C. Texier, F. Delbac, et al., *Blastocystis*, an unrecognized parasite: an overview of pathogenesis and diagnosis, *Adv. Infect. Dis.* 1 (2013) 167–178.
- [11] F. Dogruman-Al, S. Kustimur, H. Yoshikawa, C. Tuncer, Z. Simsek, M. Tanyuksel, et al., *Blastocystis* subtypes in irritable bowel syndrome and inflammatory bowel disease in Ankara, Turkey, *Mem. Inst. Oswaldo Cruz* 104 (2009) 724–727.
- [12] F. Dogruman-Al, H. Dagci, H. Yoshikawa, O. Kurt, M. Demirel, A possible link between subtype 2 and asymptomatic infections of *Blastocystis hominis*, *Parasitol. Res.* 103 (2008) 685–689.
- [13] J. Yakoob, W. Jafri, M.A. Beg, Z. Abbas, S. Naz, M. Islam, et al., Irritable bowel syndrome: is it associated with genotypes of *Blastocystis hominis*, *Parasitol. Res.* 106 (2010) 1033–1038.
- [14] P. Poirier, I. Wawrzyniak, C.P. Vivares, F. Delbac, H. El Alaoui, New insights into *Blastocystis* spp.: a potential link with irritable bowel syndrome, *PLoS Pathog.* 8 (2012), e1002545.
- [15] A. Tungtrongchitr, S. Manatsathit, C. Kositchaiwat, J. Ongrotchanakun, N. Munkong, P. Chinabut, et al., *Blastocystis hominis* infection in irritable bowel syndrome patients, *Southeast Asian J. Trop. Med. Public Health* 35 (2004) 705–710.
- [16] N.S. Idris, P.G. Dwipoerwantoro, A. Kurniawan, M. Said, Intestinal parasitic infection of immunocompromised children with diarrhoea: clinical profile and therapeutic response, *J. Infect. Dev. Ctries.* 4 (2010) 309–317.
- [17] A. Kurniawan, T. Karyadi, S.W. Dwintarsari, I.P. Sari, E. Yunihastuti, S. Djauzi, et al., Intestinal parasitic infections in HIV/AIDS patients presenting with diarrhoea in Jakarta, Indonesia, *Trans. R. Soc. Trop. Med. Hyg.* 103 (2009) 892–898.
- [18] H. Yoshikawa, N. Abe, Z. Wu, PCR-based identification of zoonotic isolates of *Blastocystis* from mammals and birds, *Microbiology* 150 (2004) 1147–1151.
- [19] K.S. Tan, New insights on classification, identification, and clinical relevance of *Blastocystis* spp., *Clin. Microbiol. Rev.* 21 (2008) 639–665.
- [20] K.F. Boorom, H. Smith, L. Nimri, E. Viscogliosi, G. Spanakos, U. Parkar, et al., Oh my aching gut: irritable bowel syndrome, *Blastocystis*, and asymptomatic infection, *Parasit. Vectors* 1 (2008) 40.
- [21] D. Stark, S. van Hal, D. Marriott, J. Ellis, J. Harkness, Irritable bowel syndrome: a review on the role of intestinal protozoa and the importance of their detection and diagnosis, *Int. J. Parasitol.* 37 (2007) 11–20.
- [22] S. Jantermtor, P. Pinlaor, K. Sawadpanich, S. Pinlaor, A. Sangka, C. Wilailuckana, et al., Subtype identification of *Blastocystis* spp. isolated from patients in a major hospital in northeastern Thailand, *Parasitol. Res.* 112 (2013) 1781–1786.
- [23] C.R. Stensvold, M. Alfellani, C.G. Clark, Levels of genetic diversity vary dramatically between *Blastocystis* subtypes, *Infect. Genet. Evol.* 12 (2012) 263–273.
- [24] M.V. Dominguez-Marquez, R. Guna, C. Munoz, M.T. Gomez-Munoz, R. Borras, High prevalence of subtype 4 among isolates of *Blastocystis hominis* from symptomatic patients of a health district of Valencia (Spain), *Parasitol. Res.* 105 (2009) 949–955.
- [25] C.R. Stensvold, D.B. Christiansen, K.E. Olsen, H.V. Nielsen, *Blastocystis* sp. subtype 4 is common in Danish *Blastocystis*-positive patients presenting with acute diarrhea, *Am. J. Trop. Med. Hyg.* 84 (2011) 883–885.
- [26] S.L. Stanley Jr., Amoebiasis, *Lancet* 361 (2003) 1025–1034.
- [27] P.P. van der Veek, M. van den Berg, Y.E. de Kroon, H.W. Verspaget, A.A. Masclee, Role of tumor necrosis factor- α and interleukin-10 gene polymorphisms in irritable bowel syndrome, *Am. J. Gastroenterol.* 100 (2005) 2510–2516.
- [28] M.M. Abou Gamra, H.S. Elwakil, H.K. El Deeb, K.E. Khalifa, H.E. Abd Elhafiz, The potential use of 29 kDa protein as a marker of pathogenicity and diagnosis of symptomatic infections with *Blastocystis hominis*, *Parasitol. Res.* 108 (2011) 1139–1146.
- [29] M.K. Puthia, S.W. Sio, J. Lu, K.S. Tan, *Blastocystis ratti* induces contact-independent apoptosis, F-actin rearrangement, and barrier function disruption in IEC-6 cells, *Infect. Immun.* 74 (2006) 4114–4123.
- [30] N. Cenac, C.N. Andrews, M. Holzhausen, K. Chapman, G. Cottrell, P. Andrade-Gordon, et al., Role for protease activity in visceral pain in irritable bowel syndrome, *J. Clin. Invest.* 117 (2007) 636–647.
- [31] K. Gece, R. Roka, L. Ferrier, M. Leveque, H. Eutamene, C. Cartier, et al., Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic luminal factor impairing colonic permeability and sensitivity, *Gut* 57 (2008) 591–598.
- [32] M.K. Puthia, A. Vaithilingam, J. Lu, K.S. Tan, Degradation of human secretory immunoglobulin A by *Blastocystis*, *Parasitol. Res.* 97 (2005) 386–389.
- [33] J. Saki, M. Foroutan-Rad, R. Asadpouri, Molecular characterization of *Cryptosporidium* spp. in wild rodents of southwestern Iran using 18s rRNA gene nested-PCR-RFLP and sequencing techniques, *J. Trop. Med.* (2016) 6834206.
- [34] M. Foroutan-Rad, S. Khademvatan, J. Saki, M. Hashemitabar, *Holothuria leucospilota* extract induces apoptosis in *Leishmania major* promastigotes, *Iran. J. Parasitol.* 11 (2016) 339–349.
- [35] H. Javaherizadeh, S. Khademvatan, S. Soltani, M. Torabizadeh, E. Yousefi, Distribution of haematological indices among subjects with *Blastocystis hominis* infection compared to controls, *Prz. Gastroenterol.* 9 (1) (2014) 38–42.